logo
I Thought I Knew Startups… Until Reality Hit Me

I Thought I Knew Startups… Until Reality Hit Me

A brutally honest story about startup education, the mistakes I made, and the ₹2,999 decision that changed everything.
They say startup life is glamorous.
Investors. Product launches. Hustle culture. Tweets. TED Talks.
I believed it all — until I started my own.
I quit my job in 2021 with a solid idea, some savings, and what I thought was enough knowledge. I had read the books, watched the YouTube gurus, followed all the right people on LinkedIn.
But guess what?
By mid-2022, I was broke, burned out, and bitter.
My startup didn't just fail. It confused me. I didn't even know why it failed.
And that haunted me.
I sat in a coffee shop one evening scrolling through my phone, trying to figure out what I missed. That's when I stumbled across a line on a forum:
'Most founders don't fail because of lack of effort. They fail because they never learned how to build a startup properly.'
That hit hard.
I didn't need another motivational video.
I needed a roadmap, not random tips.
I needed clarity on unit economics, not vague 'build what people want' quotes.
I needed to understand how to talk to investors, how to structure a pitch deck, how to know if an idea is even worth building.
That's when I discovered StartupCoE.com.
No hype. No fluff. No billionaire-founder worship.
Just a clear promise:
'Learn how to build a real startup — from idea to execution to fundraising — at just ₹2,999.'
Honestly, I was skeptical. I'd already spent more than that on coffee meetings and pitch deck templates.
But something felt different here.
Maybe it was the tone.
Maybe it was how the course spoke to people like me .
Maybe I was just ready to listen this time.
So I enrolled.
This wasn't like Udemy, where you just 'watch and forget.'
It felt like someone had reverse-engineered the entire startup journey into small, brutal truths: Why your idea might fail (and how to test it early)
How to build a business model that doesn't collapse in 6 months
How to calculate if your product can even survive in a market
How investors actually think
And how to grow without burning cash for likes and downloads
I was finally learning what no MBA or LinkedIn thread ever taught me:
Startups aren't built on motivation. They're built on systems.
I thought I was fundraising-ready before. Turns out, I was just 'pitching blind.'
The StartupCoE fundraising section walked me through: Exactly what investors expect to see at different stages
at different stages How to structure a pitch deck without sounding like a brochure
without sounding like a brochure Real mistakes founders make when reaching out to VCs
when reaching out to VCs How to build a data room, calculate unit economics, and prepare for due diligence
It didn't give me hope.
It gave me preparation. And that was far more valuable.
This was the first course that asked:
'Can your startup survive without funding?'
It changed how I thought.It changed what I built.
It made me chase customers before chasing investors.
And ironically, that's what made me fundable.
Because no one told me this stuff when I started.
Because too many brilliant founders are stuck in a loop of noise, jargon, and burnout — when all they need is clarity.
Because I wish someone had whispered in my ear earlier:
'Hey, before you burn ₹1 lakh on random tools and failed ads, maybe just spend ₹2,999 to learn how startups really work.'
And that's exactly what StartupCoE.com gave me.
No BS.No sugarcoating.
Just real lessons, for real entrepreneurs.
If you're serious about your startup…
If you want to raise funds the right way…
If you want to build something that doesn't just look good on pitch decks, but actually survives and scales …
Then do yourself a favor.
Start with StartupCoE.com.
₹2,999.One course.
Your entire mindset—rebooted.
'The best founders aren't the smartest. They're the ones who learn early what others only learn after failing.'
This is your chance to learn before the fall.
Go build it right.
— Anonymous (but real)
TIME BUSINESS NEWS

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Build Trust Fast On LinkedIn Using These 5 Content Tactics
Build Trust Fast On LinkedIn Using These 5 Content Tactics

Forbes

timean hour ago

  • Forbes

Build Trust Fast On LinkedIn Using These 5 Content Tactics

Build trust fast on LinkedIn using these 5 content tactics LinkedIn is frustrating you and it's easy to see why. You write something valuable, hit publish, and two days later it hasn't taken off, while someone else's office selfie gets 100 reactions. But giving up and saying LinkedIn doesn't work for you isn't the way forward. You're better than that. Instead, understand trust is built through strategic repetition that turns casual scrollers into loyal followers. Google's research on Zero Moments of Truth shows that it takes 11 touchpoints before someone trusts you enough to buy. Your LinkedIn content contributes to these crucial moments, but only if you package it right. The difference between posts that disappear and posts that convert lies in how you make your expertise stick in people's minds long after your post goes live. Make every post count Every LinkedIn post should be a gateway. End your posts with "How I can help you:" followed by three specific resources. Link to your detailed guide on the topic. Share the template that implements what you taught. Point to the case study proving it works. Send people down a rabbit hole of your expertise. One post becomes multiple touchpoints when you do this right. Someone reads your productivity tip, clicks through to your morning routine article, downloads your time-blocking template, and subscribes to your newsletter. They've now consumed four pieces of content from one LinkedIn post. They recognize your name, save your posts, share them with colleagues. You've accelerated trust-building without creating extra content. Watch your engagement multiply when readers comment on multiple pieces. Stock photos and polished headshots don't work on LinkedIn. Your dream clients want realness. Include photos of you at your messy desk at 6am. Share that whiteboard covered in your arty doodles. Show the coffee shop where you write your best content. Make your expertise tangible through visual proof. Personal images turn abstract advice into believable reality. Write about serving clients, and include a screenshot from a recent Zoom call. Posts with images get twice the engagement, but personal photos outperform generic graphics because they connect and help build recognition. Your face becomes familiar. Your workspace becomes memorable. Your brand becomes human. Trust grows when people feel like they know the person behind the expertise. Build trust by dropping the mask. You think you're being repetitive when you share something twice. But your ideal client missed both posts and still doesn't know what you stand for. Pick three beliefs that define your approach. Share them weekly from different angles. Tell new stories that promote the same principles. Use fresh examples for familiar concepts. LinkedIn shows each post to so few of your connections. Even devoted followers miss most of your content. Most people haven't heard that story you're tired of telling. Repeat your strongest beliefs constantly. Position yourself as the solution to your dream client's specific problem through relentless consistency. When someone finally needs what you offer, they'll immediately think of you. Your message has been drummed into their consciousness through repetition. Your content should work systematically to build relationships at scale. Add personality through LinkedIn observations like "Anyone else tired of AI-generated comments?" or "Remember when LinkedIn was just resumes?" Call out what you notice. Prove you're actively using the platform. Challenge readers directly within your posts. Ask "What would change if you implemented this today?" or "How much revenue are you leaving on the table?" Invite engagement with your ideas. Move people from passive consumption to active consideration of working with you. Build trust by making people feel seen. Ask the questions they know they need to answer. Every post should include one moment that makes someone stop scrolling and think about their situation differently, ideally in the hook. Include phrases in every post that move someone closer. Layer proof throughout your content to compound the trust. Share screenshots of client wins (with permission). Post voice notes from happy customers. Include metrics that matter to your audience. Third-party endorsements take you up a new level. Your LinkedIn presence becomes magnetic when you combine the trust tactics. Resource sections multiply your reach. Personal photos humanize your expertise. Repeated messages cement your positioning. Create an ecosystem where people can't forget you. Your consistency and commitment become another tick in the trust column. Followers become fans. Fans become superfans and, pretty soon, clients. Clients become advocates and build your business to the size you deserve. Transform your LinkedIn presence: 5 content upgrades Show up consistently with content engineered to stick in people's minds. Make your LinkedIn posts assets that work around the clock. Add resource sections, include real images, and repeat your message strategically. Your content becomes a trust-building system that turns followers into clients who already believe in your approach before they ever speak to you. Update your LinkedIn profile to attract ideal coaching clients.

Scatec ASA: Subscriptions for the Employee Share Purchase Programme 2025
Scatec ASA: Subscriptions for the Employee Share Purchase Programme 2025

Yahoo

timean hour ago

  • Yahoo

Scatec ASA: Subscriptions for the Employee Share Purchase Programme 2025

Oslo, 25 June 2025: As announced on 16 June 2025, Scatec offered participants the opportunity to purchase shares with a trading value of between NOK 10,413 and NOK 104,128. The subscription period was from 16 - 25 June 2025. The price per share has been set at NOK 89.45, based on the average volume-weighted share price on the Oslo Stock Exchange over the last five trading days during the subscription period. In total, employees have subscribed for 68,533 shares under the share purchase programme. The allocation of shares and delivery to employees is expected to take place by 4 July 2025. See attachment for an overview of the number of shares to be allocated to primary insiders who have subscribed as per end of the subscription period, as well as the notifications of the transactions in accordance with the Market Abuse Regulation Article 19. For further information, please contact:Andreas Austrell, SVP 974 38 686 About Scatec Scatec is a leading renewable energy solutions provider, accelerating access to reliable and affordable clean energy in emerging markets. As a long-term player, we develop, build, own, and operate renewable energy plants, with 6.2 GW in operation and under construction across five continents today. We are committed to grow our renewable energy capacity, delivered by our passionate employees and partners who are driven by a common vision of 'Improving our Future'. Scatec is headquartered in Oslo, Norway and listed on the Oslo Stock Exchange under the ticker symbol 'SCATC'. To learn more, visit or connect with us on LinkedIn. This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act Attachment Primary insiders subscription - Scatec

'Superbabies' Startup Seeks Funds for Controversial Gene Editing Push
'Superbabies' Startup Seeks Funds for Controversial Gene Editing Push

Yahoo

time2 hours ago

  • Yahoo

'Superbabies' Startup Seeks Funds for Controversial Gene Editing Push

(Bloomberg) -- A California-startup focused on genetically editing human embryos — a step toward creating so-called designer babies — is raising money as many of Silicon Valley's ultra-rich turn their attention to one of the most controversial technologies in medicine. Bezos Wedding Draws Protests, Soul-Searching Over Tourism in Venice US Renters Face Storm of Rising Costs US State Budget Wounds Intensify From Trump, DOGE Policy Shifts Commuters Are Caught in Johannesburg's Taxi Feuds as Transit Lags Bootstrap Bio, created about 18 months ago, is working on technology to change the DNA in an embryo, according to two people familiar with the company and one of its investors. Altering those cells to make genetically modified children is intended to eliminate inherited diseases or enhance desirable traits, which can be passed on to future generations. Scientists and ethicists said the technology known as 'germline editing' is unproven and potentially dangerous. It could have grave consequences if a flaw is introduced into a days-old embryo, with the changes affecting every cell and stage of development. If the technology does work, they fear it could usher in a new era of eugenics and foster further inequality. 'When you're messing with the safety of babies, you want to be pretty confident,' said Hank Greely, a Stanford University law professor and bioethics expert. 'We have no idea what would happen to the babies who are edited.' Experts would be especially concerned if the efforts are conducted in private laboratories without public access, oversight, review or protection, said Laurie Zoloth, a professor of religion and ethics at the University of Chicago. 'There are safer ways to avoid having a child with a genetic disease than trying to build one from scratch as if it's some sort of commodity that you put together with cool parts,' she said. Chief Executive Officer Chase Denecke and Chief Technology Officer Ben Korpan founded Bootstrap Bio after writing a viral essay using the pen names GeneSmith and kman on LessWrong, a forum popular in Silicon Valley. The essay was about about gene editing adults to make them smarter. Subsequent Reddit posts by Gene_Smith discussed the work, and Denecke — using his own name — spoke about it in an interview on YouTube. Denecke declined to comment. Korpan didn't respond to multiple requests for interviews or comment for this story. Genetic Pivot Follow up posts from Gene_Smith on Reddit detailed changes in the company's focus, including Bootstrap Bio's switch from working on gene editing the DNA of adults to plans for the genetic modification of reproductive cells. Gene_Smith said the company hired a chief science officer, opened a lab and pivoted its work, and was planning to raise seed funding earlier this year. 'When we started looking at the timelines involved to solve all the problem required for adult enhancement, it started looking like superbabies might ironically be a faster route (it's definitely simpler),' according to one Reddit post. Among Bootstrap Bio's early investors are Simone and Malcolm Collins, a couple known for advocating for higher birth rates to stave off 'demographic collapse.' The Collinses have been linked to billionaire and fellow pronatalist Elon Musk and criticized for allegedly promoting eugenics, a label they've rejected. The pair said they would consider using germline editing for some of their own embryos to minimize health risks for future children, said Simone Collins, who lost her bid for a Pennsylvania state House seat last year. 'We're going to be on that as soon as we can be,' she said, declining to specify how much the couple invested in Bootstrap Bio. 'I know that people are afraid of unforeseen knock-on effects and stuff, but being able to completely, for all future descendants, remove a risk — that's huge.' The Collinses, who refer to themselves as entrepreneurs, suggested they're less concerned about reaping financial gains from their investment in Bootstrap Bio. 'We just want them to succeed in helping people,' Simone Collins said. 'That's our investment philosophy.' Safety Regulations While even laboratory work on germline editing is highly regulated in the US, researchers have been making progress on the technology. Still, it's not ready for prime time, said Paula Amato, researcher and professor of obstetrics and gynecology at the Oregon Health and Science University. 'It's still not considered safe,' Amato said. No studies involving germline editing or genetic engineering on embryos have been disclosed on the US database tracking clinical trials. Dieter Egli, a scientist who uses the technology in his highly regulated lab at Columbia University, said more research is needed. 'Then you can ask the question, is this a technology that's sufficiently safe and effective to be used in a clinical context?' Egli said. 'That's a broader discussion.' Legal Issues Chinese researcher He Jiankui was sentenced to three years in prison and a lifelong ban from working in reproductive technology after he claimed to create the first gene-edited babies in 2018. The alteration of embryos of twin girls to allegedly reduce their risk of developing HIV was deemed an illegal practice of medicine by a Chinese court. He plans to relocate to Austin to continue working on embryonic genetic editing in a new lab, according to his posts on X this month. He said he's not interested in working with Silicon Valley investors, who he said are interested only in immortality. — Jiankui He (@Jiankui_He) June 20, 2025 Companies are required to get permission from the US Food and Drug Administration before testing novel medicines or using new technology on people. Federal law prohibits the agency from accepting any application involving genetic edits to reproductive cells, including embryos, said I. Glenn Cohen, a law professor and bioethics expert at Harvard University. There is, however, no outright ban on editing reproductive cells in the lab when done using private funding. Bootstrap Bio's future business plans, some of which have been given to investors and detailed in the YouTube interview with Denecke, included a plan to begin human trials in 2026 or 2027 in Honduras, a place where the company could potentially avoid US regulations. It's unclear if the timeline was part of the company's original focus on adult gene editing or the genetic modification of reproductive cells, and if those goals remain in place. In May, an international group of scientific societies called for a 10-year moratorium on the practice. 'There's vast, complex challenges with germline editing,' said Tim Hunt, chief executive officer of the Alliance for Regenerative Medicine, who co-authored the call for a moratorium. 'It's also unclear what is the burning medical need.' Inside Gap's Last-Ditch, Tariff-Addled Turnaround Push Luxury Counterfeiters Keep Outsmarting the Makers of $10,000 Handbags How to Steal a House Ken Griffin on Trump, Harvard and Why Novice Investors Won't Beat the Pros Is Mark Cuban the Loudmouth Billionaire that Democrats Need for 2028? ©2025 Bloomberg L.P. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store